Aromatasehemmer-assoziierte Arthralgien: klinische Erfahrungen und Therapieempfehlungen

Zusammenfassung

Fragestellung: Die Überlegenheit von Aromatasehemmern (AH) gegenüber dem Antiöstrogen Tamoxifen in der adjuvanten endokrinen Therapie bei postmenopausalen Frauen mit einem Hormonrezeptor-positiven Mammakarzinom ist mittlerweile hinreichend belegt. Allerdings wird unter der Therapie mit AH, im Gegensatz zu Tamoxifen, eine erhöhte Inzidenz von Arthralgien beschrieben. Es wird vermehrt befürchtet, dass Patientinnen wegen der AH-assoziierten Arthralgien ihre Aromatasehemmer-Behandlung vorzeitig abbrechen. Daher nehmen sowohl die Patientenaufklärung über das mögliche Auftreten von Arthralgien als auch das wirksame Management der Symptome eine bedeutende Rolle ein, um Patientinnen zur Fortsetzung ihrer AH-Behandlung zu bewegen und somit die Heilungschancen ihrer Primärerkrankung zu verbessern. Methoden: In diesem Artikel betrachten und diskutieren wir potenzielle Mechanismen, die zum Entstehen der AH-assoziierten Arthralgien führen, bewerten die Häufigkeit des Vorkommens solcher Arthralgien und schlagen einen spezifischen Algorithmus für die Therapie Aromatasehemmer-assoziierter Arthralgien vor. So wird – wie auch bei Gelenkbeschwerden anderer Patienten ohne Mammakarzinom – ein sequenzieller Therapieansatz zum Management der Beschwerden empfohlen. Dieser beinhaltet neben einem veränderten individuellen Lebensstil einen Stufenplan zur medikamentösen Intervention mit Analgetika und antientzündlichen Substanzen. Schlussfolgerung: Die Erkenntnis, dass Gelenkbeschwerden bei den meisten Patientinnen gut handhabbar sind, kann sowohl das Arzt-Patienten-Verhältnis als auch die Patienten-Compliance verbessern. Ein spezifischer Algorithmus für die Therapie kann Arzt und Patientin im Umgang mit Aromatasehemmer-assoziierten Arthralgien unterstützen.

Abstract

Objective: It is well documented that aromatase inhibitors (AI) are superior to tamoxifen as an adjuvant endocrine therapy in postmenopausal women with hormone receptor-positive breast cancer. However, compared with tamoxifen, an elevated incidence of arthralgia has been observed during AI treatment. Concerns have been raised that AI-induced arthralgia may dissuade patients from completing their full AI treatment course. Patient education on the possibility of experiencing arthralgia and the effective management of symptoms, if they appear, is important in helping patients adhere to AI treatment schedules and, consequently, in improving breast cancer outcomes. Methods: In this paper, we discuss the potential mechanisms behind AI-induced arthralgia, review the frequency with which arthralgia occurs, and propose an algorithm specifically for the treatment of AI-induced arthralgia. As with joint pain in non-breast cancer patients, a sequential approach to disease management is recommended, involving modifications of the patient's lifestyle in addition to taking a stratified approach to pharmacological intervention with analgesia and anti-inflammatory medication. Conclusion: Knowing that joint symptoms can be managed in most patients may encourage patient-physician communication and treatment compliance. A specific treatment algorithm is proposed that may support doctors and patients when dealing with AI-induced arthralgia.

Aromatasehemmer - Arthralgie - COX‐2‐selektives NSAR (Coxib) - Gelenkschmerzen - traditionelle nicht steroidale Antirheumatika (tNSAR)

aromatase inhibitors - arthralgia - coxib - joint pain - tNSAID

Literatur

• 1 Early Breast Cancer Trialists' Collaborative Group . Tamoxifen for early breast cancer.  Cochrane Database Syst Rev. 2004; 
• 2 Buzdar A U. Aromatase inhibitors: changing the face of endocrine therapy for breast cancer.  Breast Dis. 2005;  24 107-117
• 3 Coates A S, Keshaviah A, Thurlimann B. et al . Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.  J Clin Oncol. 2007;  25 486-492
• 4 Coombes R C, Kilburn L S, Snowdon C F. et al . Survival and safety of exemestane versus tamoxifen after 2 – 3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.  Lancet. 2007;  369 559-570
• 5 Goss P E, Ingle J N, Martino S. et al . Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.  J Natl Cancer Inst. 2005;  97 1262-1271
• 6 ATAC Trialists' Group . Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.  Lancet. 2005;  365 60-62
• 7 Mouridsen H T. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.  Curr Med Res Opin. 2006;  22 1609-1621
• 8 Conte P, Frassoldati A. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.  Breast J. 2007;  13 28-35
• 9 Jonat W, Hilpert F, Kaufmann M. Aromatase inhibitors: a safety comparison.  Expert Opin Drug Saf. 2007;  6 165-174
• 10 Eastell R. Aromatase inhibitors and bone.  J Steroid Biochem Mol Biol. 2007;  106 157-161
• 11 Golding D, Wilson P. Rheumatism and the menopause.  Practitioner. 1989;  233 314 316-318
• 12 Sueblinvong T, Taechakraichhana N, Phupong V. Prevalence of climacteric symptoms according to years after menopause.  J Med Assoc Thai. 2001;  84 1681-1691
• 13 Cecil R L, Archer B H. Arthritis of the menopause.  JAMA. 1925;  84 75-79
• 14 Felson D T, Cummings S R. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation.  Arthritis Rheum. 2005;  52 2594-2598
• 15 Schaible H G, Schmelz M, Tegeder I. Pathophysiology and treatment of pain in joint disease.  Adv Drug Deliv Rev. 2006;  58 323-342
• 16 Burstein H J. Aromatase inhibitor-associated arthralgia syndrome.  Breast. 2007;  16 223-234
• 17 Buzdar A U ATAC Trialists' Group on behalf of the. Clinical features of joint symptoms observed in the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial.  J Clin Oncol. 2006;  24 (Suppl. 18) abs 551
• 18 The ATAC Trialists' Group . Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.  Lancet Oncol. 2006;  7 633-643
• 19 Morales L, Pans S, Westhovens R. et al .Importance of synovial fluid retention and thickening in patients with severe musculoskeletal pains treated with letrozole or exemestane: a case series describing the impact of symptoms, clinical findings and magnetic resonance imaging. Poster 4056 presented at the San Antonio Breast Cancer Symposium, 2006. 
• 20 Kidd B L. Osteoarthritis and joint pain.  Pain. 2006;  123 6-9
• 21 Schaible H G. Spinal mechanisms contributing to joint pain.  Novartis Found Symp. 2004;  260 4-22
• 22 Kidd B L, Photiou A, Inglis J J. The role of inflammatory mediators on nociception and pain in arthritis.  Novartis Found Symp. 2004;  260 122-133
• 23 Vegeto E, Bonincontro C, Pollio G. et al . Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia.  J Neurosci. 2001;  21 1809-1818
• 24 Dawson-Basoa M E, Gintzler A R. Estrogen and progesterone activate spinal kappa-opiate receptor analgesic mechanisms.  Pain. 1996;  64 608-615
• 25 Ho S C, Chan S G, Yip Y B, Cheng A, Yi Q, Chan C. Menopausal symptoms and symptom clustering in Chinese women.  Maturitas. 1999;  33 219-227
• 26 Randolph Jr J F, Sowers M, Bondarenko I V, Harlow S D, Luborsky J L, Little R J. Change in estradiol and follicle-stimulating hormone across the early menopausal transition: effects of ethnicity and age.  J Clin Endocrinol Metab. 2004;  89 1555-1561
• 27 Cauley J A, Gutai J P, Kuller L H, LeDonne D, Powell J G. The epidemiology of serum sex hormones in postmenopausal women.  Am J Epidemiol. 1989;  129 1120-1131
• 28 Richette P, Corvol M, Bardin T. Estrogens, cartilage, and osteoarthritis.  Joint Bone Spine. 2003;  70 257-262
• 29 Greendale G A, Reboussin B A, Hogan P. et al . Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial.  Obstet Gynecol. 1998;  92 982-988
• 30 Nevitt M C, Felson D T, Williams E N, Grady D. The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial.  Arthritis Rheum. 2001;  44 811-818
• 31 Grunfeld E A, Hunter M S, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen.  Patient Educ Couns. 2005;  59 97-102
• 32 Lash T L, Fox M P, Westrup J L, Fink A K, Silliman R A. Adherence to tamoxifen over the five-year course.  Breast Cancer Res Treat. 2006;  99 215-220
• 33 Huang C, Ross P D, Lydick E, Wasnich R D. Factors associated with joint pain among postmenopausal women.  Int J Obes Relat Metab Disord. 1997;  21 349-354
• 34 Roddy E, Doherty M. Changing life-styles and osteoarthritis: what is the evidence?.  Best Pract Res Clin Rheumatol. 2006;  20 81-97
• 35 Messier S P, Loeser R F, Miller G D. et al . Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis: the Arthritis, Diet, and Activity Promotion Trial.  Arthritis Rheum. 2004;  50 1501-1510
• 36 Dieppe P A, Lohmander L S. Pathogenesis and management of pain in osteoarthritis.  Lancet. 2005;  365 965-973
• 37 Bolten W W. Differential analgesic treatment in arthrosis and arthritis.  MMW Fortschr Med. 2004;  146 39-42
• 38 Bolten W W. Symptomatic therapy of rheumatic diseases. How they reduce pain and thereby safe costs.  MMW Fortschr Med. 2002;  144 30-36
• 39 ACR Subcommittee on Osteoarthritis . Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines.  Arthritis Rheum. 2000;  43 1905-1915
• 40 Clemett D, Goa K L. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.  Drugs. 2000;  59 957-980
• 41 Urban M K. COX‐2 specific inhibitors offer improved advantages over traditional NSAIDs.  Orthopedics. 2000;  23 S761-S764
• 42 Hawkins C, Hanks G W. The gastroduodenal toxicity of nonsteroidal anti-inflammatory drugs: a review of the literature.  J Pain Symptom Manage. 2000;  20 140-151
• 43 Fitzgerald G A. Coxibs and cardiovascular disease.  N Engl J Med. 2004;  351 1709-1711
• 44 Bolten W W. Recommendations for treatment with nonsteroidal anti-inflammatory drugs.  MMW Fortschr Med. 2005;  147 24-27
• 45 Huober J, Wagner U, Wallwiener W. Der Stellenwert der Aromatasehemmer der dritten Generation in der adjuvanten Therapie – Zeit zum Umdenken.  Geburtsh Frauenheilk. 2002;  62 15-21
• 46 Wenderlein J M. Aromatasehemmer riskant für das Gehirn?.  Geburtsh Frauenheilk. 2005;  65 144-148
• 47 Hyllested M, Jones S, Pedersen J L, Kehlet H. Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review.  Br J Anaesth. 2002;  88 199-214
• 48 Braithwaite R S, Chlebowski R T, Lau J, George S, Hess R, Col N F. Meta-analysis of vascular and neoplastic events associated with tamoxifen.  J Gen Intern Med. 2003;  18 937-947
• 49 McCaig F M, Renshaw L, Hannon R. et al . A randomised study of the impact of endocrine therapy for breast cancer on bone turnover and quality of life.  EJC Supplements. 6; 7 52-53
• 50 Buzdar A, Chlebowski R, Cuzick J. et al . Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.  Curr Med Res Opin. 2006;  22 1575-1585
• 51 Ergebnis der Arbeitsgruppe Arthralgien vom 1. Februar 2007: Cancer Treatment Reviews manuscript in press; modifiziert nach WW Bolten, Argumente Fakten der medizin (2) 2006.